Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate with Estramustine and Docetaxel in HRPC
NCT00151073Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Apr 2002
- Primary completion
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in prostate cancer (PCa) (2 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percent Increase/Decrease in Bone Markers from Baseline to Cycle 2 Day 2. Started Apr 2002; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00151073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151073.